Published 11 hours ago • loading... • Updated 11 hours ago

Palatin Technologies Announces Closing of Reduced Public Offering

Palatin Technologies, Inc., a biopharmaceutical company, announced on May 8, 2025, from Cranbury, N.J., the closing of its reduced public offering on the OTC Pink market under the symbol PTNT.
The offering followed SEC approval on May 6, 2025, and included institutional and accredited investor participation, with Palatin recently transitioning to OTC Pink after delisting from major exchanges.
The offering included 7,324,119 common shares along with Series F warrants exercisable immediately at a $0.30 price per share, all sold at $0.15 each, with the company planning to allocate the proceeds mainly toward operational expenses and broader corporate needs.
Palatin received approximately $1.1 million in gross proceeds, with lead placement by A.G.P./Alliance Global Partners and co-placement by Laidlaw & Company Ltd., while highlighting forward-looking statements about potential further warrant exercises.
This funding event supports Palatin's strategy to advance its first-in-class melanocortin receptor-targeted medicines addressing unmet medical needs, while recognizing risks inherent in forward-looking projections.

Insights by Ground AI

Does this summary seem wrong?